Roche announced a new “Liver Disease Panel,” which it says is the first certified suite of digital algorithms designed to help clinicians detect and manage chronic liver disease (CLD) earlier and more efficiently.
Key points from the announcement:
- The panel focuses heavily on identifying liver fibrosis and MASLD/MASH using routine lab data instead of invasive biopsies.
- Its flagship tool, called LiverPRO (developed with Evido), uses a patient’s age plus common blood biomarkers to estimate fibrosis risk.
- Roche positions the platform as a scalable, non-invasive screening approach that can help primary care and specialty practices identify at-risk patients earlier.
- The broader strategy is to move liver disease care from a reactive model to a preventive, population-health model using AI/digital diagnostics.
- Roche highlighted the growing prevalence of MASLD, driven by obesity and diabetes, and noted that earlier detection could reduce progression to cirrhosis and liver cancer.
- This fits into Roche’s broader liver disease push, which includes:
- the recent Elecsys PRO-C3 fibrosis assay launch,
- and acquisitions/investments in MASH therapeutics like 89bio.
Strategically, Roche appears to be building an end-to-end liver disease ecosystem:
- population screening and risk stratification,
- fibrosis diagnostics,
- longitudinal monitoring,
- and eventually therapy selection/support for MASH treatments.
For companies in virtual liver care and risk-identification workflows, this is another signal that major diagnostics players are moving aggressively into AI-enabled liver disease management.
